PTEN (the phosphatase that directly opposes the oncogenic signaling pathways) loss is the major or crucial step due to which the event of PI3K signaling gets hyperactive, and it’s connected with the negative result in the patient with prostate cancer. This evidence concerns the gene PTEN and prostate cancer.